NCT02314013

Brief Summary

The aim of the present study was to evaluate whether antibiotics is mandatory for the treatment of acute uncomplicated right-sided diverticulitis. The hypothesis is that patients having acute uncomplicated diverticulitis at right-sided colon will be recovered without antibiotics.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
132

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2014

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

November 20, 2014

Completed
20 days until next milestone

First Posted

Study publicly available on registry

December 10, 2014

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2018

Completed
Last Updated

November 16, 2016

Status Verified

April 1, 2016

Enrollment Period

2.6 years

First QC Date

November 20, 2014

Last Update Submit

November 14, 2016

Conditions

Keywords

uncomplicated diverticulitis, economic cost, hospital stay

Outcome Measures

Primary Outcomes (1)

  • Treatment Failure

    advancement or recurrence diverticulitis at the same site.

    4-6 weeks

Secondary Outcomes (2)

  • length of hospital stay at first admission for diverticulitis

    up to 2 weeks

  • total cost of hospitalization for diverticulitis

    up to 2 weeks

Study Arms (2)

Cephalosporin + Metronidazole

ACTIVE COMPARATOR

intravenous antibiotics injection (3rd generation cephalosporin + metronidazole) and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)

Drug: Cephalosporin + Metronidazole

No antibiotic

NO INTERVENTION

bowel rest and then, discharge until tolerable soft diet.

Interventions

intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)

Cephalosporin + Metronidazole

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Right-sided colonic diverticulitis
  • Uncomplicated diverticulitis

You may not qualify if:

  • Pregnancy
  • Refuse to investigation
  • Immunosuppressive therapy or immunologic incompetence
  • Colonic diverticulitis except right-sided diverticulitis
  • Complicated diverticulitis
  • Disorder of psychology or cognition
  • Allergic reaction to antibiotics being used in the study (3rd generation cephalosporin, quinolone, metronidazole)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Surgery, Dongtan Sacred Heart Hospital, Hallym University College of Medicine

Hwaseong-si, Gyeonggi-do, 445-170, South Korea

Location

Related Publications (1)

  • Kim JY, Park SG, Kang HJ, Lim YA, Pak KH, Yoo T, Cho WT, Shin DW, Kim JW. Prospective randomized clinical trial of uncomplicated right-sided colonic diverticulitis: antibiotics versus no antibiotics. Int J Colorectal Dis. 2019 Aug;34(8):1413-1420. doi: 10.1007/s00384-019-03343-w. Epub 2019 Jul 2.

MeSH Terms

Interventions

CephalosporinsMetronidazole

Intervention Hierarchy (Ancestors)

beta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsNitroimidazolesNitro CompoundsImidazolesAzolesHeterocyclic Compounds, 1-Ring

Study Officials

  • Jong Wan Kim, MD

    Department of Surgery, Dongtan Sacred Heart Hospital, Hallym University College of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 20, 2014

First Posted

December 10, 2014

Study Start

April 1, 2014

Primary Completion

November 1, 2016

Study Completion

February 1, 2018

Last Updated

November 16, 2016

Record last verified: 2016-04

Locations